Lecithin- cholesterol acyltransferase and relationship with Platelet-activating factor in AB blood phenotype

• Published in: Bali medical journal Vol. 9; no. 1; pp. 332 - 338
• Main Authors: Birinci, Suayip, Koctekin, Belkis, Yilmaz, Necat
• Format: Journal Article
• Language: English
• Published: 01.01.2020
• ISSN: 2089-1180; 2302-2914
• DOI: 10.15562/bmj.v9i1.1746

Objectives: This study aimed to determine the association between Lecithin-cholesterol acyltransferase (LCAT) and Platelet-activating factor (PAF) with atherogenic potential in the ABO blood system.Background: The current study is the first study that focuses on healthy blood donors and investigating a relationship between ABO blood groups and LCAT enzyme and PAF, which plays a notable role in atherogenesis.Methods: ABO blood types characterize the role of the individualistic phenotype. Hence, it is generally assumed that ABO blood phenotypes are involved with many diseases. This cross-sectional study involved 176 healthy subjects with different ABO blood phenotypes. Measurements of routine lipids, LCAT, PAF and atherogenic plasma index (AIP) were performed in these subjects.Results: Our most important finding was that individuals with blood group AB have statistically significant lower LCAT levels in serum. Additionally, there was a moderately negative correlation between LCAT and triglycerides in the AB blood phenotype (r=-0.452, P=0.02). Nevertheless, there were statistically significant correlations between LCAT levels and PAF levels of subjects with only non –O blood phenotypes (A, B and AB). Serum AIP values were statistically significantly higher in the AB blood group.Conclusion: The present study suggests that blood group AB can be associated with decreased LCAT   levels when compared to the non- AB phenotypes. We suggest that LACT and AIP may be helpful biomarkers to illustrate atherogenic risk in AB blood phenotype, although this requires further investigation.